Patients who develop immunotherapy-related colitis tend to have better outcomes, so it is important to get them back on treatment as soon as possible.
Immunotherapy-related colitis is a "hot topic" in the world of oncology, according to Yinghong Wang, MD, PhD, MS, gastroenterologist, Department of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center. It is important that the healthcare team treat patients with colitis quickly and effectively, so that they can get back on treatment as soon as possible, and stay on treatment as well.
This is a hot topic because we see so many patients who have colitis from checkpoint inhibitors and we want to improve our quality of service to get the patients’ symptoms under control as soon as possible and as effectively as possible. Patients who develop GI-related toxicity tend to have a better cancer outcome. Therefore, our goal is to put them back on the immunotherapy as fast as possible and keep them on as long as possible.